Printer Friendly

BURROUGHS WELLCOME COMPANY AWARDED 1991 CORPORATE LEADERSHIP AWARD FROM THE NATIONAL HEMOPHILIA FOUNDATION FOR COMMITMENT TO FIGHTS AIDS

BURROUGHS WELLCOME COMPANY AWARDED 1991 CORPORATE LEADERSHIP AWARD FROM THE NATIONAL HEMOPHILIA FOUNDATION FOR COMMITMENT TO FIGHTS AIDS
 NEW YORK, Nov. 6 /PRNewswire/ -- The Burroughs Wellcome Company of Research Triangle Park, North Carolina received the 1991 Corporate Leadership Award of the National Hemophilia Foundation at the organization's recent meeting in Tampa, Florida.
 The pharmaceutical company, the developer and distributor of the Retrovir(R) brand zidovudine, known popularly at AZT, and a number of other specialized drugs to treat various manifestations of HIV/AIDS, received the award "in recognition of their commitment to fight AIDS," and "their commitment to the hemophilia community," according to the award notice.
 "Burroughs Wellcome has shown both compassion and leadership in the fight against the AIDS epidemic, not only by general patient assistance programs that could provide as much as $10 million annually in free medicine to people with HIV infection, but also by their outstanding support of the NHF AIDS Fund and their support of AIDS research protocols that include members of the hemophilia community," said NHF Executive Director Alan P. Brownstein.
 The Burroughs Wellcome patient assistance program, established in 1987, was expanded this year due to the increasing impact of HIV infection and associated illnesses. The program is designed to speed access to therapy for HIV-infected people until they can secure reimbursement from public or private sources.
 Two new aspects of the program provide patients with vouchers to receive Burroughs Wellcome AIDS medication at most U.S. pharmacies: and the formation of an advisory committee of healthcare experts and representatives of the HIV community to recommend changes and improvements in the program.
 "We are very grateful for this recognition by the National Hemophilia Foundation," said Philip R. Tracy, president and chief executive officer of Burroughs Wellcome. "This program demonstrates the company's ongoing commitment to providing medicines to people with life-threatening diseases and no means of payment. The program is continually enhanced in response to the evolving needs of people with HIV and those who provide their medical care."
 The company has been closely involved with assisting people with hemophilia who are HIV positive. It is estimated that some 50 percent of the nation's approximately 20,000 people with hemophilia are HIV positive, almost all from the use of blood products that promote clotting that were contaminated with HIV.
 Burroughs Wellcome Company, a research-based pharmaceutical company, is a wholly-owned subsidiary of the Wellcome Foundation Ltd., headquartered in London.
 -0- 11/6/91
 /CONTACT: Mary Anne Ramer, National Hemophilia Foundation, 212-219-8180/ CO: Burroughs Wellcome Company; National Hemophilia Foundation ST: North Carolina IN: MTC SU: DF -- CH001 -- 1550 11/06/91 09:03 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 6, 1991
Words:437
Previous Article:ICN PHARMACEUTICALS INC. AND ITS SUBSIDIARIES APPROVE CHANGING THE COMPANIES'S FISCAL YEAR TO COINCIDE WITH THE CALENDAR YEAR
Next Article:VISHAY REPORTS THIRD QUARTER AND NINE MONTHS' RESULTS
Topics:


Related Articles
PILOT STUDY SUGGESTS SAFETY AND EFFECTIVENESS OF 566 A NEW INVESTIGATIONAL PCP THERAPY
BURROUGHS WELLCOME GIVES $1 MILLION TO COMMUNITY-BASED CLINICAL RESEARCH
BURROUGHS WELLCOME CO. SUPPORTS HURRICANE RELIEF EFFORT
BURROUGHS WELLCOME SUES NOVOPHARM FOR PATENT INFRINGEMENT
MEPRON(TM) NOW AVAILABLE AS TREATMENT FOR PCP
MISS AMERICA VISITS BURROUGHS WELLCOME CO.
BURROUGHS WELLCOME WINS PATENT LAWSUIT
DU PONT MERCK WILL CO-PROMOTE NEW WELLCOME EPILEPSY DRUG
BURROUGHS WELLCOME DEDICATES MEMORIAL ON WORLD AIDS DAY
TRIANGLE PHARMACEUTICALS COMPLETES FINANCING; NEW FIRM, LED BY EX-WELLCOME R&D HEAD DR. DAVID BARRY

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters